TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05077111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Anesthesia
Description: Group A pre-medicated once using Midazolam 3-4mg intravenous (IV) and Fentanyl 50mcg, placed in the setting position. Using a winged 18G (Gadge), 9cm length Tuohy Epidural needle, a 20G springwound closed tip epidural catheter be inserted between T3-T4. A test dose (5ml) 2% Lidocaine given, followed by 5-8 ml Bupivacaine 0.5% and 50mcg Fentanyl as a loading dose. Further top-up dose of 5 ml Bupivicaine 0.5% after 45 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia with One Lung Ventilation
Description: Group B premedicated once by 3-4mg Midazolam IV, Ranitidine 50mg, Metoclopramide 10mg and Dexamethasone 4mg. Preoxygenation with 100% O2. Induction of anesthesia with Propofol (2mg/kg) and Fentanyl (1mcg/kg). Tracheal intubation by 37-39 Fr Double Lumen Endotracheal Tube insertion facilitated with Cisatracurium 0.1mg/kg. and confirmation of its position by Fiberoptic Bronchoscopy. Selective Lung Ventilation strategy can be performed through the endobroncheal tube of the non operated lung once needed. Anesthesia maintained with Isoflurane (1-2%) and Cisatracurium (0.05mg/kg per dose). Later, anesthesia discontinued and extubation after full neuromuscular recovery after reversal of muscle relaxant by Neostigmine (0.05mg/kg) and Atropine (0.02mg/kg).
Study: NCT04264845

Intervention type: OTHER
Intervention: Provider Focus
Description: The provider focus groups will be conducted and data from the focus group sessions will be analyzed and used to evaluate clinicians' interpretation of PROs and acceptability of PRO data in routine clinical care. A formal provider training program will be designed and implemented by a subject matter expert. The focus group session will be repeated at 12 months, with the 12month administration having an increased emphasis on barriers, facilitators, and value of PROs in clinical care.
Study: NCT00691041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unity in Diversity
Description: HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
Study: NCT02121717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar
Description: Take orally
Study: NCT00404781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol in addition to aspirin and clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol in addition to aspirin and clopidogrel
Study: NCT00085540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depsipeptide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depsipeptide
Description: Given IV
Study: NCT06058494

Intervention type: PROCEDURE
Intervention: Anterior Cruciate Ligament Reconstruction
Description: Reconstruction of the anterior cruciate ligament by means of the three reported techniques, namely single-bundle, single-bundle with extraarticular tenodesis and anatomic double-bundle.

Intervention type: PROCEDURE
Intervention: Anterior Cruciate Ligament Reconstruction
Description: Reconstruction of the anterior cruciate ligament by means of the three reported techniques, namely single-bundle, single-bundle with extraarticular tenodesis and anatomic double-bundle.

Intervention type: PROCEDURE
Intervention: Anterior Cruciate Ligament Reconstruction
Description: Reconstruction of the anterior cruciate ligament by means of the three reported techniques, namely single-bundle, single-bundle with extraarticular tenodesis and anatomic double-bundle.
Study: NCT00273858

Intervention type: OTHER
Intervention: There is no Intervention. The study is observational.
Description: The study is observational and the prescription follows the SmPC of etanercept.
Study: NCT02285764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: Modified carbohydrate

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: As determined by the study site
Study: NCT02733692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Understanding Reproductive Health for Ladeez (GURHL) Code
Description: Understanding Reproductive Health for Ladeez (GURHL) Code is an acceptability study to test a web-based application designed with and for young women of color 18 to 25 years old.
Study: NCT00585299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Description: 20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional diet
Description: Traditional low-fat diet with dietitian follow-up in 16 weeks
Study: NCT04264845

Intervention type: OTHER
Intervention: Patient Interview
Description: A trained professional interviewer will conduct a one-time, one-hour, semi-structured telephone interview of each subject to better understand patient experiences with HF, the treatment process and quality of life determinants. Two semistructured interviews will be conducted with the first 30 patients who have had LVAD therapy (of the 100 patients who agreed to be interviewed), before and 12 months after device implantation. The goal of these interviews will be to describe patient experiences with LVAD therapy, examine factors influencing quality of life, and determine whether currently available PRO tools are likely to capture the intended experiences in HF as they relate to LVAD therapy.
Study: NCT00585299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional diet
Description: Traditional low-fat diet with dietitian follow-up in 16 weeks
Study: NCT03471091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV with the integrated tele-monitoring management program
Description: Noninvasive positive pressure ventilation with the integrated tele-monitoring management will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly.
Study: NCT01000064

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vyvanse
Description: 30 mg - 70 mg capsules taken every morning for 6 weeks.
Study: NCT04264845

Intervention type: OTHER
Intervention: PROs/Clinical Data Integration
Description: A plan has been developed that will integrate PRO scores into patient medical records. Information will be obtained from 2 instruments (KCCQ12 and NIH PROMIS) that are routinely administered as part standard of care. PRO and clinical data will be obtained from electronic medical records of patients seen in the heart failure clinic. All required information will be obtained from the subjects' electronic medical records over a period of 3.5 years after enrollment into the study.
Study: NCT04164160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated-care-model benefiting group
Description: Patients will be called for the ﬁrst interview of the study by the healthcare professional. Their data will be automatically entered in the Salut + Social app, they will be asked to respond to the study questionnaires (ad hoc questionnaire for sociodemographic data, EuroQol-5D, Zarit questionnaire and Morisky-Green test) and will take part in the future actions to be planned for them. Patients will receive an appointment to attend their PCC at 6, 9, and 12 months after their incorporation into the program. In those follow-up, the same questionnaires will be provided together with the IEXPAC questionnaire, which evaluates the experience of the chronic patient with the new care model.
Study: NCT02121717

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chiglitazar
Description: Take orally
Study: NCT01000064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vyvanse
Description: 30 mg - 70 mg capsules taken every morning for 6 weeks.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fMRI
Description: Brain scans (fMRI) performed at baseline, 6 week visit and 12th week visit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: Brain scans (fMRI) performed at baseline, 6 week visit and 12th week visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules taken every morning for 6 weeks.
Study: NCT04038099

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water-Based Vaginal Lubricant
Description: 5cc water based jelly applied intraurethral
Study: NCT01000064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo capsules taken every morning for 6 weeks.
Study: NCT04844047

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: refer to arm descriptors

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: refer to arm descriptors
Study: NCT02268565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81mg aspirin daily at bedtime over a 2 week period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pill that looks like aspirin without the effects of aspirin
Study: NCT01145027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast tray
Description: The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste.
Study: NCT03716063

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jianpi Huatan dispensing granule
Description: once a day in the morning and evening, every month for a course of treatment, a total of three courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jianpi Huatan dispensing granule
Description: once a day in the morning and evening, every month for a course of treatment, a total of three courses
Study: NCT00832754

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RDT
Description: Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RDT
Description: Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Judgement as basis for treatment of malaria with ACT
Description: Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Judgement as basis for treatment of malaria with ACT
Description: Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
Study: NCT04038099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine topical
Description: 5cc 2% lidocaine jelly applied intraurethral
Study: NCT01728389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrabone transplantation
Description: Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
Study: NCT02649790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-8602
Description: Participants will receive KPT-8602 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-8602
Description: Participants will receive KPT-8602 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-8602
Description: Participants will receive KPT-8602 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-8602
Description: Participants will receive KPT-8602 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-8602
Description: Participants will receive KPT-8602 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-8602
Description: Participants will receive KPT-8602 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-8602
Description: Participants will receive KPT-8602 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-8602
Description: Participants will receive KPT-8602 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-8602
Description: Participants will receive KPT-8602 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-8602
Description: Participants will receive KPT-8602 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 is a combination drug of 35 mg decitabine and 100 mg cedazuridine.
Study: NCT02121717

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take orally
Study: NCT02319850

Intervention type: RADIATION
Intervention: DXA scanning
Description: Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).

Intervention type: RADIATION
Intervention: DXA scanning
Description: Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
Study: NCT00843089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
Study: NCT01148069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery combined with IMRT-IGRT
Description: Patients will have surgery consisting in extensive pelvic dissection and ablation of seminal vesicles. Surgery will be followed by prolonged hormonotherapy (3 years) associated, after 2 months, with prostatic only irradiation.
Study: NCT02510872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET combined with CT with iodinated contrast injection
Study: NCT03920618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
Study: NCT02111941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Description: Given ID
Study: NCT02510872

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 18F-FDG PET combined with CT without injection
Study: NCT03142620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 40mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 40mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 40mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: 1000mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: 1000mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: 1000mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 500mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 500mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 500mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 5000IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 5000IU
Study: NCT00770952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Glimepiride
Description: Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks.
Study: NCT02248714

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucerna SR
Description: Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.
Study: NCT01008709

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Teleflex HemoLock clip
Description: Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aesculap U-clip
Description: Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
Study: NCT02233374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early MRI and PET/CT - 2 weeks after commencing chemo/RT
Description: Patients will have an early MRI and PET/CT - 2 weeks after commencing chemo/RT. A limited range PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late MRI and PET/CT 6 weeks post chemo/RT
Description: Patients will have late a MRI and PET/CT 6 weeks post chemo/RT. A whole body PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
Study: NCT04581122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Patients with ground glass nodules smaller than 3cm and with more than 50%solid components would randomly assigned to selective lymphadenectomy group or systematic lymph node dissection group
Study: NCT01977456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Description: IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
Study: NCT02649790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive dexamethasone oral tablets.
Study: NCT01349751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isobaric levobupivacaine
Description: 0.42% either isobaric levobupivacaine 3 ml spinal injection once
Study: NCT01922895

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Rhamnosus GG
Description: Probiotic nutritional supplement; Lactobacillus Rhamnosus GG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Probiotic
Description: Capsule manufactured without active ingredients.
Study: NCT01349751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric levobupivacaine
Description: 0.42% hyperbaric levobupivacaine 3 ml spinal injection once
Study: NCT00996086

Intervention type: DEVICE
Intervention: CRT device implant
Description: CRT device-recipients
Study: NCT01770860

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6660
Description: At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
Study: NCT01259492

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Placebo
Study: NCT01770860

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4314
Description: At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 8336
Description: At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 4840
Description: At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.